RT Journal Article
T1 Danio Rerio as Model Organism for Adenoviral Vector Evaluation
A1 Gulías Otero, Paola
A1 Guerra Varela, Jorge
A1 González Aparicio, Manuela
A1 Ricobaraza, Ana
A1 Vales, Africa
A1 González Aseguinolaza, Gloria
A1 Hernández Alcoceba, Rubén
A1 Sánchez Piñón, Laura
K1 Danio rerio
K1 Adenovirus
K1 High-capacity adenoviral vector
K1 Helper-dependent adenovirus
K1 Delivery system
K1 Gene therapy
AB Viral vector use is wide-spread in the field of gene therapy, with new clinical trials starting every year for different human pathologies and a growing number of agents being approved by regulatory agencies. However, preclinical testing is long and expensive, especially during the early stages of development. Nowadays, the model organism par excellence is the mouse (Mus musculus), and there are few investigations in which alternative models are used. Here, we assess the possibility of using zebrafish (Danio rerio) as an in vivo model for adenoviral vectors. We describe how E1/E3-deleted adenoviral vectors achieve efficient transduction when they are administered to zebrafish embryos via intracranial injection. In addition, helper-dependent (high-capacity) adenoviral vectors allow sustained transgene expression in this organism. Taking into account the wide repertoire of genetically modified zebrafish lines, the ethical aspects, and the affordability of this model, we conclude that zebrafish could be an efficient alternative for the early-stage preclinical evaluation of adenoviral vectors
PB MDPI
YR 2019
FD 2019
LK http://hdl.handle.net/10347/21404
UL http://hdl.handle.net/10347/21404
LA eng
NO Gulías, P.; Guerra-Varela, J.; Gonzalez-Aparicio, M.; Ricobaraza, A.; Vales, A.; Gonzalez-Aseguinolaza, G.; Hernandez-Alcoceba, R.; Sánchez, L. Danio Rerio as Model Organism for Adenoviral Vector Evaluation. Genes 2019, 10, 1053
NO This research was funded by Xunta de Galicia, Local Government, grant number ED431C 2018/28, and Gobierno de Navarra, Local Government, grant numbers 0011-1383-2018-000011 PT038 and 0011-1383-2019-000006 PT013 (XANTOGEN)
DS Minerva
RD 24 abr 2026